ABT

SEC source: 0001415889-24-005080 · form4-02232024_100223.xml · derivative · entry 3

Boudreau Philip P · CIK 0001805099 · SENIOR VICE PRESIDENT

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 86,519

Underlying: Common Shares · 86,519 shares

Expires 2034-02-20

F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 28,839 on February 21, 2025, 28,840 on February 21, 2026, and 28,840 on February 21, 2027.

SEC source: 0001415889-24-005080 · form4-02232024_100223.xml · nonDerivative · entry 1

Boudreau Philip P · CIK 0001805099 · SENIOR VICE PRESIDENT

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,091

F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.

SEC source: 0001415889-24-005088 · form4-02232024_100230.xml · derivative · entry 3

Ford Robert B · CIK 0001612571 · Director · CHAIRMAN AND CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 264,293

Underlying: Common Shares · 264,293 shares

Expires 2034-02-20

F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 88,097 on February 21, 2025, 88,098 on February 21, 2026, and 88,098 on February 21, 2027.

SEC source: 0001415889-24-005088 · form4-02232024_100230.xml · nonDerivative · entry 1

Ford Robert B · CIK 0001612571 · Director · CHAIRMAN AND CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 251,669

F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.

SEC source: 0001415889-24-005092 · form4-02232024_100245.xml · derivative · entry 6

Funck, Jr. Robert E. · CIK 0001565892 · EXECUTIVE VICE PRESIDENT

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 92,137

Underlying: Common Shares · 92,137 shares

Expires 2034-02-20

F5 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 30,712 on February 21, 2025, 30,712 on February 21, 2026, and 30,713 on February 21, 2027.

SEC source: 0001415889-24-005092 · form4-02232024_100245.xml · nonDerivative · entry 1

Funck, Jr. Robert E. · CIK 0001565892 · EXECUTIVE VICE PRESIDENT

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 222,756

F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.

SEC source: 0001415889-24-005098 · form4-02232024_100219.xml · derivative · entry 2

Earnhardt Lisa D · CIK 0001530893 · EXECUTIVE VICE PRESIDENT

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 64,787

Underlying: Common Shares · 64,787 shares

Expires 2034-02-20

F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 21,595 on February 21, 2025, 21,596 on February 21, 2026, and 21,596 on February 21, 2027.

SEC source: 0001415889-24-005098 · form4-02232024_100219.xml · nonDerivative · entry 1

Earnhardt Lisa D · CIK 0001530893 · EXECUTIVE VICE PRESIDENT

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 92,677

F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.

SEC source: 0001415889-24-005101 · form4-02232024_100234.xml · derivative · entry 3

MCCOY JOHN A. JR. · CIK 0001644207 · VICE PRESIDENT

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,563

Underlying: Common Shares · 16,563 shares

Expires 2034-02-20

F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 5,521 on February 21, 2025, 5,521 on February 21, 2026, and 5,521 on February 1, 2027.

SEC source: 0001415889-24-005101 · form4-02232024_100234.xml · nonDerivative · entry 1

MCCOY JOHN A. JR. · CIK 0001644207 · VICE PRESIDENT

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,153

F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.

SEC source: 0001415889-24-005105 · form4-02232024_100217.xml · derivative · entry 3

Moreland Mary K · CIK 0001783147 · EXECUTIVE VICE PRESIDENT

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,734

Underlying: Common Shares · 39,734 shares

Expires 2034-02-20

F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 13,244 on February 21, 2025, 13,245 on February 21, 2026, and 13,245 on February 21, 2027.

SEC source: 0001415889-24-005105 · form4-02232024_100217.xml · nonDerivative · entry 1

Moreland Mary K · CIK 0001783147 · EXECUTIVE VICE PRESIDENT

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 97,798

F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.

SEC source: 0001415889-24-005107 · form4-02232024_100240.xml · derivative · entry 3

Morrone Louis H. · CIK 0001867666 · EXECUTIVE VICE PRESIDENT

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 46,257

Underlying: Common Shares · 46,257 shares

Expires 2034-02-20

F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 15,419 on February 21, 2025, 15,419 on February 21, 2026, and 15,419 on February 21, 2027.

SEC source: 0001415889-24-005107 · form4-02232024_100240.xml · nonDerivative · entry 1

Morrone Louis H. · CIK 0001867666 · EXECUTIVE VICE PRESIDENT

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 67,224

F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.

SEC source: 0001415889-24-005109 · form4-02232024_100201.xml · derivative · entry 2

Salvadori Daniel Gesua Sive · CIK 0001620564 · EXECUTIVE VICE PRESIDENT

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 58,898

Underlying: Common Shares · 58,898 shares

Expires 2034-02-20

F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 19,632 on February 21, 2025, 19,633 on February 21, 2026, and 19,633 on February 21, 2027.

SEC source: 0001415889-24-005109 · form4-02232024_100201.xml · nonDerivative · entry 1

Salvadori Daniel Gesua Sive · CIK 0001620564 · EXECUTIVE VICE PRESIDENT

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 135,534

F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.

SEC source: 0001415889-24-005110 · form4-02232024_100243.xml · derivative · entry 2

Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 51,397

Underlying: Common Shares · 51,397 shares

Expires 2034-02-20

F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 17,132 on February 21, 2025, 17,132 on February 21, 2026, and 17,133 on February 21, 2027.

SEC source: 0001415889-24-005110 · form4-02232024_100243.xml · nonDerivative · entry 1

Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 78,704

F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.

SEC source: 0001415889-24-002080 · form4-01312024_100152.xml · derivative · entry 6

Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 46,949

Underlying: Common Shares · 17,500 shares

Expires 2028-02-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.

SEC source: 0001415889-24-002080 · form4-01312024_100152.xml · derivative · entry 5

Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 13,271

Underlying: Common Shares · 25,000 shares

Expires 2027-02-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.

SEC source: 0001415889-24-002080 · form4-01312024_100152.xml · nonDerivative · entry 4

Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 65,027

SEC source: 0001415889-24-002080 · form4-01312024_100152.xml · nonDerivative · entry 3

Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 82,527

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-24-002080 · form4-01312024_100152.xml · nonDerivative · entry 2

Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 65,027

SEC source: 0001415889-24-002080 · form4-01312024_100152.xml · nonDerivative · entry 1

Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 90,027

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-24-000359 · form4-01032024_100123.xml · derivative · entry 1

Alpern Robert J · CIK 0001448074 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,512

Underlying: Common Shares · 71 shares

Expires not disclosed

F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

SEC source: 0001415889-24-000361 · form4-01032024_100135.xml · derivative · entry 1

Gonzalez Patricia Paola · CIK 0001879701 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,870

Underlying: Common Shares · 299 shares

Expires not disclosed

F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

SEC source: 0001415889-24-000362 · form4-01032024_100152.xml · derivative · entry 1

Roman Michael F · CIK 0001577544 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,324

Underlying: Common Shares · 320 shares

Expires not disclosed

F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

SEC source: 0001415889-24-000367 · form4-01032024_100108.xml · derivative · entry 1

Stratton John G · CIK 0001385262 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,114

Underlying: Common Shares · 333 shares

Expires not disclosed

F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

SEC source: 0001415889-23-016642 · form4-12182023_101216.xml · derivative · entry 3

Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 38,271

Underlying: Common Shares · 15,000 shares

Expires 2027-02-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.

SEC source: 0001415889-23-016642 · form4-12182023_101216.xml · nonDerivative · entry 2

Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 65,027

SEC source: 0001415889-23-016642 · form4-12182023_101216.xml · nonDerivative · entry 1

Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 80,027

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001104659-23-112618 · tm2329263-1_4seq1.xml · nonDerivative · entry 2

STARKS DANIEL J · CIK 0000902132 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 6,725,316

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $94.06 to $94.72, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

SEC source: 0001104659-23-112618 · tm2329263-1_4seq1.xml · nonDerivative · entry 1

STARKS DANIEL J · CIK 0000902132 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 6,748,409

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $93.06 to $94.05, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

SEC source: 0001415889-23-013947 · form4-10032023_101054.xml · derivative · entry 1

Alpern Robert J · CIK 0001448074 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,392

Underlying: Common Shares · 81 shares

Expires not disclosed

F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

SEC source: 0001415889-23-013948 · form4-10032023_101019.xml · derivative · entry 1

Gonzalez Patricia Paola · CIK 0001879701 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,557

Underlying: Common Shares · 340 shares

Expires not disclosed

F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

SEC source: 0001415889-23-013949 · form4-10032023_101048.xml · derivative · entry 1

Roman Michael F · CIK 0001577544 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,988

Underlying: Common Shares · 363 shares

Expires not disclosed

F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

SEC source: 0001415889-23-013950 · form4-10032023_101002.xml · derivative · entry 1

Stratton John G · CIK 0001385262 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,729

Underlying: Common Shares · 379 shares

Expires not disclosed

F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

SEC source: 0001415889-23-013307 · form4-09152023_090915.xml · nonDerivative · entry 3

Funck, Jr. Robert E. · CIK 0001565892 · EXECUTIVE VICE PRESIDENT

10b5-1 filing: No plan indicated

Ownership: Indirect · By Trust

Disclosed balance after: 20,000

F1 · balance_after: Held in daughter's annual gift trust. The reporting person disclaims beneficial ownership of all securities held by the trust.

SEC source: 0001415889-23-013307 · form4-09152023_090915.xml · nonDerivative · entry 2

Funck, Jr. Robert E. · CIK 0001565892 · EXECUTIVE VICE PRESIDENT

10b5-1 filing: No plan indicated

Ownership: Indirect · By Trust

Disclosed balance after: 20,000

F1 · balance_after: Held in daughter's annual gift trust. The reporting person disclaims beneficial ownership of all securities held by the trust.

SEC source: 0001415889-23-013307 · form4-09152023_090915.xml · nonDerivative · entry 1

Funck, Jr. Robert E. · CIK 0001565892 · EXECUTIVE VICE PRESIDENT

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 198,237

SEC source: 0001415889-23-013035 · form4-09062023_100916.xml · derivative · entry 3

MCCOY JOHN A. JR. · CIK 0001644207 · VICE PRESIDENT

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,071

Underlying: Common Shares · 2,071 shares

Expires 2033-08-31

F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 690 on September 1, 2024, 690 on September 1, 2025, and 691 on September 1, 2026.

SEC source: 0001415889-23-013035 · form4-09062023_100916.xml · nonDerivative · entry 1

MCCOY JOHN A. JR. · CIK 0001644207 · VICE PRESIDENT

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,746

F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.

SEC source: 0001415889-23-013036 · form4-09062023_100916.xml · derivative · entry 3

Boudreau Philip P · CIK 0001805099 · SENIOR VICE PRESIDENT

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,223

Underlying: Common Shares · 10,223 shares

Expires 2033-08-31

F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 3,407 on September 1, 2024, 3,408 on September 1, 2025, and 3,408 on September 1, 2026.

SEC source: 0001415889-23-013036 · form4-09062023_100916.xml · nonDerivative · entry 1

Boudreau Philip P · CIK 0001805099 · SENIOR VICE PRESIDENT

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,067

F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.

SEC source: 0001415889-23-012074 · form4-08102023_100835.xml · derivative · entry 8

Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 5,000 shares

Expires 2026-02-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.

SEC source: 0001415889-23-012074 · form4-08102023_100835.xml · nonDerivative · entry 7

Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 65,027

SEC source: 0001415889-23-012074 · form4-08102023_100835.xml · nonDerivative · entry 6

Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 65,043

SEC source: 0001415889-23-012074 · form4-08102023_100835.xml · nonDerivative · entry 5

Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 65,315

SEC source: 0001415889-23-012074 · form4-08102023_100835.xml · nonDerivative · entry 4

Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 70,427

SEC source: 0001415889-23-012074 · form4-08102023_100835.xml · nonDerivative · entry 3

Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 70,442